Hikma appoints Henriette Nielsen as Chief Transformation Officer

London, 4 June 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces the appointment of Henriette Nielsen to the newly created role of Chief Transformation Officer. In this role, Henriette will be responsible for leading a number of initiatives across Hikma’s global operations to improve operational efficiency and ensure that Hikma achieves its strategic objectives. She will join Hikma’s Executive Committee and will report directly to Siggi Olafsson, Hikma’s Chief Executive Officer. Her appointment is effective from 4 June 2018.

Press Release Corporate 4 June 2018

Siggi Olafsson said, “Henriette brings extensive experience in pharmaceutical operations and transformation projects and has a strong track record of formulating and executing global strategic initiatives and developing multi-functional work plans. She brings an entrepreneurial attitude that I am confident will fit well within the Hikma culture.”

Henriette joins Hikma from Teva Pharmaceuticals USA, where she was most recently Senior Vice President, Chief Transformation Officer, Global Marketing & Portfolio. Her previous experience includes founder of System Matters, a healthcare and impact investing consultancy, and General Counsel and EVP at Actavis Group. She also held senior roles at Alpharma, Netdoktor and Kromann Reumert.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.